TheraRadar
Data updated: May 26, 2026

IDKIT:HP (citric acid)

Cardiovascular Approved 2002-12-17

IDKIT:HP (Anticoagulant Citrate Dextrose Solution USP, Solution A) is an anticoagulant solution used during the preparation of Platelet Rich Plasma (PRP) products. It maintains blood in a fluid state during processing within specialized medical devices. This solution is intended only for the extracorporeal preparation of PRP to prevent clotting of blood components during the procedure.

Source: FDA Label • MERIDIAN BIOSCIENCE
Jump to: Indications Approvals Trials Competitors Similar Safety Patents

How IDKIT:HP Works

This solution acts as an extracorporeal anticoagulant by binding free calcium in the blood, a necessary co-factor for several steps in the clotting cascade. Sodium citrate is the primary component responsible for anticoagulation, while citric acid is included for pH regulation and dextrose is added for isotonicity. This solution has no pharmacological effect.

Source: FDA Label
1
Indication
--
Phase 3 Trials
23
Years on Market

Details

Status
Prescription
First Approved
2002-12-17
Routes
ORAL
Dosage Forms
FOR SOLUTION, TABLET, FOR SOLUTION

Companies

MERIDIAN BIOSCIENCE
Active Ingredient: CITRIC ACID , UREA C-13

IDKIT:HP Approval History

2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2002 to 2016
Jul 2016 SUPPL
Mfg · Manufacturing (CMC)
Jul 2016 SUPPL
Mfg · Manufacturing (CMC)
FDA Letter
Oct 2014 SUPPL
Label · Labeling
FDA Letter Label

What IDKIT:HP Treats

2 indications

IDKIT:HP is approved for 2 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Extracorporeal blood clotting
  • Platelet Rich Plasma (PRP) preparation
Source: FDA Label

Drugs Similar to IDKIT:HP

3 of 8

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
DEXTROSE
2 shared
B BRAUN
Shared indications:
Extracorporeal blood clottingPlatelet Rich Plasma (PRP) preparation
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
DEXTROSE
1 shared
B BRAUN
Shared indications:
Platelet Rich Plasma (PRP) preparation
DEXTROSE 20% IN PLASTIC CONTAINER
DEXTROSE
1 shared
OTSUKA ICU MEDCL
Shared indications:
Extracorporeal blood clotting
View all 8 similar drugs Pro
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT03769402 52-376 Ph 4 completed The Influence of Citric Acid Bone Surface Etching and Bone Defect Fill on GCF BMP-2 Release Profile
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IDKIT:HP FDA Label Details

Indications & Usage

FDA Label (PDF)

IDKIT:HP is indicated for the treatment of Extracorporeal blood clotting; Platelet Rich Plasma (PRP) preparation.

Track IDKIT:HP with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA021314 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.